Skip to main content

LDN and Multiple Sclerosis (MS) – A Potential Gamechanger You Need to Know

LDN and Multiple Sclerosis

Multiple Sclerosis (MS) patients are increasingly turning to Low Dose Naltrexone (LDN) as a potential gamechanger in their treatment. LDN is an emerging therapy that has shown promise in reducing symptoms and improving quality of life for individuals living with MS. This article explores the potential benefits of LDN and its impact on the management of MS.

Low dose naltrexone (LDN) is a new and promising treatment option for a variety of chronic diseases. It has been found to be potentially effective in those with autoimmune disorders such as multiple sclerosis, Crohn’s disease, and fibromyalgia. LDN works by blocking the receptors in the body that are responsible for pain relief. By blocking these receptors, it reduces inflammation and pain associated with many chronic diseases. LDN has been found to be safe and well-tolerated in clinical trials and is now being used by as an alternative treatment option for those suffering from chronic illnesses like MS.

LDN and Multiple Sclerosis Studies

In 2008, a six-month pilot trial was conducted by the San Raffaele Scientific Institute in Italy to test LDN on 40 patients with primary progressive multiple sclerosis (PPMS). The primary goal was to see if LDN is a safe and tolerable treatment. The results of this trial showed that LDN is indeed safe and tolerable, and during the six-month period neurological disability progression was halted in all but one patient.

In 2010, University of California San Francisco conducted another pilot trial. 60 subjects with MS participated in the trial to assess LDN’s effects on mental health quality of life (QoL). The study results showed that LDN use was associated with a significant improvement in several mental health quality of life measures, including pain relief.

In 2015, the Jondi-Shapoor University of Medical Sciences performed a double-blind study to see how much LDN could improve quality of life for MS patients. In this trial, 96 MS patients were split into two groups. At the end of the 4-month trial, the authors concluded that LDN was a safe treatment, and proposed that a longer trial duration would be needed to show meaningful improvements in physical and mental health.

Various types of MS and their symptoms have been studied in both human and animal trials. These include relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and symptoms including pain, spasticity, fatigue, depression, clinically isolated syndrome, and quality of life (QoL).

LDN and Multiple Sclerosis Results

Several animal trials have been conducted in order to try and identify the specific type of MS that is most likely to benefit from LDN. LDN shows signs of being a safe and promising candidate for treating MS, and is already being prescribed by hundreds of physicians worldwide for treating patients suffering from MS.



Trinova Health is a licensed pharmacy located in Tampa, Florida that only engages in compounding in response to a practitioners prescription. A written prescription from a licensed practitioner is required for compounded medication from our pharmacy. The information on the site is general in nature and is only intended for use as an educational tool. You should consult your physician or a Trinova Health pharmacist if you have any specific questions relating to the diagnosis and treatment of any health problems. Information and statements about products and health conditions have not been evaluated by the Food and Drugs Administration (FDA), nor has the FDA approved the products to diagnose, cure or prevent disease. For any questions regarding our pharmacy or Low Dose Naltrexone, we can be reached at 844-219-2139 or


Dr. Eugene Papantoniou

Dr. Eugene Papantoniou has ten years’ experience as a clinical compounding pharmacist with extensive operational and managerial experience at an independent compounding pharmacy. Dr. Papantoniou assisted the pharmacist-in-charge with maintaining all standard operating procedures especially as it relates to quality control, testing programs, and regulatory reporting. Dr. Papantoniou maintains an active interest in low dose naltrexone (LDN) research, mental health, men’s health and fitness/wellness enhancement.

Leave a Reply

Close Menu

Trinova Health

1209 Tech Blvd.
Suite 102
Tampa, FL 33619

T: 813-551-1165